newsfilter
← Earnings
Earnings Releases·

Acrivon Therapeutics — Third Quarter 2026 Earnings Summary

Acrivon Therapeutics reported a net loss of $17.9 million for the third quarter of 2026, with cash and investments totaling $77.8 million expected to fund operations through the fourth quarter of 2027. The company established immunology and inflammation as a second strategic pillar, acquiring the Phase 2-ready JAK1 inhibitor ACR-525 for eosinophilic esophagitis and a preclinical PKCθ program. Clinical progress includes late-breaking data on the WEE1/PKMYT1 inhibitor ACR-2316 showing durable responses in lung and endometrial cancers, while the CHK1/2 inhibitor ACR-368 is on track for a prespecified interim analysis in endometrial cancer later this year. Additionally, the CDK11 inhibitor ACR-7280 has been nominated for IND-enabling studies in acute myeloid leukemia.

Company
ACRIVON THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology